Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up

Nadezhda P Cvetkova, Kristina Hölldobler, Philipp Prahs, Viola Radeck, Horst Helbig, David Märker Department of Ophthalmology, University of Regensburg, Regensburg, Germany Purpose: Our aim was to evaluate an optical coherence tomography (OCT) and visual acuity (VA)-guided, varia...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cvetkova NP, Hölldobler K, Prahs P, Radeck V, Helbig H, Märker D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	AMD neovascular OCT Ranibizumab Retina Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/034123d2f1cb4cb182f09727e4b49dd7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:034123d2f1cb4cb182f09727e4b49dd7
record_format	dspace
spelling	oai:doaj.org-article:034123d2f1cb4cb182f09727e4b49dd72021-12-02T05:53:01ZRanibizumab in neovascular age-related macular degeneration: a 5-year follow-up1177-5483https://doaj.org/article/034123d2f1cb4cb182f09727e4b49dd72016-06-01T00:00:00Zhttps://www.dovepress.com/ranibizumab-in-neovascular-age-related-macular-degeneration-a-5-year-f-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Nadezhda P Cvetkova, Kristina Hölldobler, Philipp Prahs, Viola Radeck, Horst Helbig, David Märker Department of Ophthalmology, University of Regensburg, Regensburg, Germany Purpose: Our aim was to evaluate an optical coherence tomography (OCT) and visual acuity (VA)-guided, variable-dosing regimen with intravitreal ranibizumab injection for treating patients with neovascular age-related macular degeneration (AMD) from 2007 to 2012. Design: This was a retrospective clinical study of 5 years follow-up in a tertiary eye center. Patients and methods: In this study, 66 patients with neovascular AMD (mean age of 74 years, SD 8.7 years) were included. We investigated the development of best-corrected visual acuity (BCVA), the number of intravitreal injections, and the central retinal thickness measured with OCT (OCT Spectralis) over 5 years of intravitreal treatment. Results: The mean number of intravitreal ranibizumab injections over 5 years was 8.8. The mean BCVA before therapy was 0.4 logarithm of the minimum angle of resolution (logMAR). After 5 years of therapy, the mean BCVA was 0.6 logMAR. In all, 16% of treated patients had stable VA over 5 years and 10% of study eyes approved their VA. The mean OCT-measured central retinal thickness at the beginning of this study was 295 µm; after 5 years of treatment, the mean central retinal thickness was 315 µm. There was an increase in central retinal thickness in 47.5% of examined eyes. Conclusion: Other studies showed VA improvement in OCT-guided variable-dosing regimens. Our study revealed a moderate decrease in VA after a total mean injection number as low as 8.8 injections over 5 years. In OCT, an increase in central retinal thickness over 5 years could be observed. Probably, this is due to deficient treatment when comparing the total injection number to other treatment regimens. Anti-VEGF therapy helps to keep the VA stable for a period of time, but cannot totally stop the progression of the disease completely. Patients with late stages of neovascular AMD can maintain VA even if they are relatively undertreated. Keywords: AMD, neovascular, OCT, ranibizumab, retinaCvetkova NPHölldobler KPrahs PRadeck VHelbig HMärker DDove Medical PressarticleAMDneovascularOCTRanibizumabRetinaOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 1047-1051 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	AMD neovascular OCT Ranibizumab Retina Ophthalmology RE1-994
spellingShingle	AMD neovascular OCT Ranibizumab Retina Ophthalmology RE1-994 Cvetkova NP Hölldobler K Prahs P Radeck V Helbig H Märker D Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
description	Nadezhda P Cvetkova, Kristina Hölldobler, Philipp Prahs, Viola Radeck, Horst Helbig, David Märker Department of Ophthalmology, University of Regensburg, Regensburg, Germany Purpose: Our aim was to evaluate an optical coherence tomography (OCT) and visual acuity (VA)-guided, variable-dosing regimen with intravitreal ranibizumab injection for treating patients with neovascular age-related macular degeneration (AMD) from 2007 to 2012. Design: This was a retrospective clinical study of 5 years follow-up in a tertiary eye center. Patients and methods: In this study, 66 patients with neovascular AMD (mean age of 74 years, SD 8.7 years) were included. We investigated the development of best-corrected visual acuity (BCVA), the number of intravitreal injections, and the central retinal thickness measured with OCT (OCT Spectralis) over 5 years of intravitreal treatment. Results: The mean number of intravitreal ranibizumab injections over 5 years was 8.8. The mean BCVA before therapy was 0.4 logarithm of the minimum angle of resolution (logMAR). After 5 years of therapy, the mean BCVA was 0.6 logMAR. In all, 16% of treated patients had stable VA over 5 years and 10% of study eyes approved their VA. The mean OCT-measured central retinal thickness at the beginning of this study was 295 µm; after 5 years of treatment, the mean central retinal thickness was 315 µm. There was an increase in central retinal thickness in 47.5% of examined eyes. Conclusion: Other studies showed VA improvement in OCT-guided variable-dosing regimens. Our study revealed a moderate decrease in VA after a total mean injection number as low as 8.8 injections over 5 years. In OCT, an increase in central retinal thickness over 5 years could be observed. Probably, this is due to deficient treatment when comparing the total injection number to other treatment regimens. Anti-VEGF therapy helps to keep the VA stable for a period of time, but cannot totally stop the progression of the disease completely. Patients with late stages of neovascular AMD can maintain VA even if they are relatively undertreated. Keywords: AMD, neovascular, OCT, ranibizumab, retina
format	article
author	Cvetkova NP Hölldobler K Prahs P Radeck V Helbig H Märker D
author_facet	Cvetkova NP Hölldobler K Prahs P Radeck V Helbig H Märker D
author_sort	Cvetkova NP
title	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
title_short	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
title_full	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
title_fullStr	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
title_full_unstemmed	Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
title_sort	ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/034123d2f1cb4cb182f09727e4b49dd7
work_keys_str_mv	AT cvetkovanp ranibizumabinneovascularagerelatedmaculardegenerationa5yearfollowup AT holldoblerk ranibizumabinneovascularagerelatedmaculardegenerationa5yearfollowup AT prahsp ranibizumabinneovascularagerelatedmaculardegenerationa5yearfollowup AT radeckv ranibizumabinneovascularagerelatedmaculardegenerationa5yearfollowup AT helbigh ranibizumabinneovascularagerelatedmaculardegenerationa5yearfollowup AT markerd ranibizumabinneovascularagerelatedmaculardegenerationa5yearfollowup
_version_	1718400152257953792

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up

Ejemplares similares